BPC-157 Dosage Guide: Protocols, Routes, and How to Use It Safely
Explore the clinic directoryIn this article
The typical BPC-157 dosage is 200 to 800 mcg per day for most adults, most often given as 250 to 500 mcg once or twice daily by subcutaneous injection. With a 5 mg vial mixed in 2 mL of bacteriostatic water, 200 to 800 mcg per day equals 0.08 to 0.32 mL, or 8 to 32 units on a U-100 insulin syringe, and a single 250 mcg dose is 0.1 mL (10 units).
These ranges come from practitioner consensus scaled up from animal research, much of it by Predrag Sikiric's group at the University of Zagreb. BPC-157 is not approved by the US Food and Drug Administration (FDA) for any medical use, so no official human dose exists.
Key Takeaways
- Practitioners commonly use 200 to 800 mcg of BPC-157 per day, scaled by body weight and split into one or two doses; this is consensus, not FDA labeling.
- A 5 mg vial reconstituted with 2 mL of bacteriostatic water holds 2,500 mcg per mL, so every 10 units on a U-100 insulin syringe delivers 250 mcg.
- Typical cycles run 4 to 6 weeks on and 2 to 4 weeks off, and oral gut protocols often run 6 to 8 weeks.
- A 2025 systematic review in HSS Journal by Vasireddi and colleagues found 35 preclinical studies and only 1 clinical study of BPC-157 for musculoskeletal use.
- The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding, citing immunogenicity, impurities and limited human safety data.
At a Glance
- Typical dose: 200-800 mcg/day for most adults, split into 1-2 administrations
- Routes: Subcutaneous injection (most studied), oral (gut-specific), intramuscular
- Cycle length: 4-6 weeks on, 2-4 weeks off is the most common protocol
- Reconstitution: Bacteriostatic water; store refrigerated once mixed
- Stacking: Frequently paired with TB-500 for synergistic tissue repair
What Is BPC-157 and Why Does Dosing Matter?
BPC-157 (Body Protection Compound-157, also called pentadecapeptide BPC 157 or PL 14736 in early research) is a synthetic 15 amino acid peptide derived from a protein found in human gastric juice. In animal studies, it has sped healing of tendons, ligaments, muscle, gut lining and bone. Human evidence is thin, so dose, route and timing are the main variables a prescriber can control.
Next step: Read the peptide therapy guide, then find vetted clinics that list BPC-157 and related peptides.
This guide breaks down the protocols practitioners and researchers use, the differences between subcutaneous and oral dosing, how to convert a dose into mL and syringe units, how to reconstitute and inject, and how stacking with TB-500 is typically structured. For a full overview of this peptide, see our complete BPC-157 guide.
BPC-157 is usually prescribed as part of peptide therapy by physicians in sports medicine, functional medicine, integrative medicine and anti-aging practices, often alongside PRP, prolotherapy or physical therapy. Our BPC-157 treatment overview covers its mechanism and the conditions it is studied for.
How Much BPC-157 Per Day in mL and Units?
A daily BPC-157 dose of 200 to 800 mcg equals 0.08 to 0.32 mL per day when a 5 mg vial is mixed with 2 mL of bacteriostatic water. On a U-100 insulin syringe, where 1 unit is 0.01 mL, that is 8 to 32 units per day. The conversion changes whenever the amount of water added to the vial changes.
How do you convert mcg to mL and units?
Divide the dose in mcg by the concentration in mcg per mL to get mL, then multiply by 100 to get units on a U-100 syringe. At 2,500 mcg per mL, a 500 mcg dose is 500 divided by 2,500, which is 0.2 mL, or 20 units.
| Dose (5 mg vial + 2 mL BAC water) | Volume | Units on a U-100 insulin syringe |
|---|---|---|
| 200 mcg | 0.08 mL | 8 units |
| 250 mcg | 0.10 mL | 10 units |
| 300 mcg | 0.12 mL | 12 units |
| 400 mcg | 0.16 mL | 16 units |
| 500 mcg | 0.20 mL | 20 units |
| 800 mcg | 0.32 mL | 32 units |
What does a twice daily schedule look like in units?
A person using 250 mcg twice daily injects 10 units in the morning and 10 units in the evening from a 2 mL mixed vial, which totals 0.2 mL and 500 mcg per day. At that pace a 5 mg vial lasts 10 days. Labels on gray market vials are not always accurate, which is one reason prescribers favor a documented source.
Subcutaneous vs. Oral BPC-157: Choosing Your Route
The right route depends on the target tissue. Subcutaneous injection is used for musculoskeletal injuries, and oral BPC-157 is used mainly for the gut.
Subcutaneous Injection
Subcutaneous (subQ) injection is the most commonly studied route in animal research and the most popular among practitioners. The peptide enters the bloodstream relatively quickly and can act systemically. For a joint, tendon, ligament or muscle injury, subQ injection near the injury site is the usual practitioner recommendation.
Advantages: higher bioavailability, ability to inject close to the injury site, well studied in preclinical models. Drawbacks: requires reconstitution, needles and proper sterile technique. According to the Vasireddi review (2025), BPC-157 has a half-life of under 30 minutes in animal studies, which is one reason many protocols split the daily dose.
Oral Administration
BPC-157 is one of the rare peptides that appears to retain biological activity when taken orally, in rodent studies. This fits its origin as a fragment of a gastric juice protein that is stable in the GI tract. Oral dosing is used mostly for gut conditions such as Crohn's disease and other inflammatory bowel disease, leaky gut, gastric ulcers and NSAID-induced GI damage.
Advantages: no needles, convenient, may suit GI healing better. Drawbacks: lower systemic bioavailability, less studied for musculoskeletal targets. Our post on BPC-157 for gut healing goes deeper on oral protocols.
| Factor | Subcutaneous Injection | Oral Administration |
|---|---|---|
| Best for | Tendons, ligaments, joints, muscle | Gut lining, GI inflammation, ulcers |
| Bioavailability | High (systemic) | Lower systemic; high local GI |
| Typical dose | 200-400 mcg, 1-2x daily | 250-500 mcg, 1-2x daily |
| Ease of use | Moderate (requires reconstitution) | Easy (capsule or liquid) |
| Onset of effects | Often within 1-2 weeks | Often within 1-3 weeks for GI |
The onset times in this table are practitioner and user reports, not trial results. Intramuscular injection is a third route some prescribers use, with doses in the same range as subcutaneous injection.
BPC-157 Dosing by Body Weight
The most commonly referenced dosing range in preclinical research is roughly 1-10 mcg per kilogram of body weight per day. Practitioners have translated this into human doses. Here is the general framework:
General Dosing Guidelines
- Under 150 lbs (68 kg): 200-400 mcg/day
- 150-200 lbs (68-91 kg): 300-600 mcg/day
- Over 200 lbs (91 kg): 400-800 mcg/day
These ranges reflect practitioner consensus, not FDA-approved dosing. Start at the lower end and adjust based on response.
Most people split the daily dose into two administrations: once in the morning and once in the evening. Some practitioners recommend a single daily dose for simplicity, especially at the lower end of the range.
In syringe terms, using the 2 mL mixing ratio above, a person under 150 lbs would draw 8 to 16 units per day, a person of 150 to 200 lbs 12 to 24 units, and a person over 200 lbs 16 to 32 units.
Cycling Protocols: How Long to Run BPC-157
BPC-157 is usually run in cycles rather than indefinitely. Practitioners say cycling may limit desensitization and gives time to reassess, though no human study has tested cycle length.
| Protocol | Route | Time on | Time off |
|---|---|---|---|
| Standard | Subcutaneous | 4 weeks | 2 weeks |
| Extended | Subcutaneous | 6 weeks, sometimes 8 | 2 to 4 weeks |
| Gut healing | Oral | 6 to 8 weeks | 2 to 4 weeks |
Standard Protocol
4 weeks on, 2 weeks off. This is the most widely recommended cycle for general musculoskeletal injuries. After the off period, reassess. Many people find that one or two cycles are sufficient for mild to moderate injuries.
Extended Protocol
6 weeks on, 2-4 weeks off. Used for more severe or chronic injuries, post-surgical recovery, or stubborn tendinopathies. Some practitioners extend to 8 weeks for complex cases, though this is less common.
Gut Healing Protocol
6-8 weeks of oral BPC-157, sometimes combined with other gut-supportive interventions. GI conditions often require longer protocols because mucosal healing is a slower process. Reassess symptoms and, if needed, run a second cycle after a 2-4 week break.
How to Reconstitute BPC-157
BPC-157 typically comes as a lyophilized (freeze-dried) powder in a vial, usually containing 5 mg. You will need bacteriostatic water (BAC water), insulin syringes and alcohol swabs. The steps below are the ones a prescribing clinic usually demonstrates at the first visit.
- Step 1: Clean the tops of both the BPC-157 vial and the BAC water vial with alcohol swabs.
- Step 2: Draw your desired amount of BAC water into the syringe. A common reconstitution is 2 mL of BAC water into a 5 mg vial. This gives you 2,500 mcg per mL, or 250 mcg per 0.1 mL (10 units on an insulin syringe).
- Step 3: Inject the BAC water into the BPC-157 vial slowly, aiming the stream along the glass wall. Do not spray it directly onto the powder. Let it dissolve gently. Do not shake the vial.
- Step 4: Once fully dissolved, store the vial in the refrigerator. Reconstituted BPC-157 is generally considered stable for about 3-4 weeks when refrigerated.
Reconstitution Quick Reference (5 mg vial)
| BAC Water Added | Concentration | 250 mcg = | 500 mcg = |
|---|---|---|---|
| 1 mL | 5,000 mcg/mL | 5 units | 10 units |
| 2 mL | 2,500 mcg/mL | 10 units | 20 units |
| 3 mL | 1,666 mcg/mL | 15 units | 30 units |
More water makes each unit weaker and each dose larger in volume, which some people find easier to measure accurately. Less water makes doses smaller in volume. Whatever ratio you use, write the concentration on the vial so every dose is drawn the same way.
Injection Sites and Technique
For subcutaneous injection, the general principle is to inject as close to the injury site as practical. You are not injecting into the joint or tendon itself; you are injecting into the fatty tissue nearby. Injections into a joint are a different procedure that only a clinician should perform.
Common injection sites:
- Shoulder injuries: Subcutaneous injection into the deltoid area or surrounding tissue
- Knee injuries: Fatty tissue around the knee, just below or to the side of the kneecap
- Achilles/ankle: Subcutaneous tissue near the Achilles tendon
- Elbow (tennis/golfer’s elbow): Subcutaneous tissue near the lateral or medial epicondyle
- Abdominal injection: For systemic effects or when the injury site is difficult to reach, the lower abdominal fat pad works well
Use a 29-31 gauge insulin syringe. Pinch the skin, insert the needle at a 45-degree angle, inject slowly, and withdraw. Rotate injection sites to avoid irritation.
The injury types above overlap with the conditions people most often ask peptide clinics about, including tennis elbow, Achilles tendinopathy and general joint pain. Standard care such as physical therapy usually continues alongside any peptide protocol.
Stacking BPC-157 with TB-500
TB-500 is a synthetic fragment of Thymosin Beta-4, another peptide with tissue repair properties. Where BPC-157 appears to work mainly through growth factor modulation and angiogenesis, TB-500 promotes cell migration and reduces inflammation through different pathways in animal studies. The two are frequently combined because their mechanisms appear to complement each other.
A typical stacking protocol:
| Peptide | Loading Phase (Weeks 1-2) | Maintenance (Weeks 3-6) |
|---|---|---|
| BPC-157 | 250-500 mcg, 2x daily | 250-500 mcg, 1x daily |
| TB-500 | 2-2.5 mg, 2x per week | 2-2.5 mg, 1x per week |
They can be injected at the same time (in the same syringe or separate syringes at the same site). Many practitioners report that the combination produces faster and more complete healing than either peptide alone, though controlled human trials comparing the stack to monotherapy are lacking. Learn more about peptide combinations in our peptide therapy guide.
The BPC-157 plus TB-500 pairing is sometimes sold as a named blend; our overview of the Wolverine stack explains what that label usually contains, and the TB-500 peptide guide covers TB-500 dosing on its own.
Safety Considerations and Side Effects
BPC-157 has a favorable safety profile in preclinical research, but human safety data is very limited. Sikiric's group reports that no lethal dose was identified in their animal studies, which is unusual for a bioactive compound. According to the 2025 systematic review by Vasireddi and colleagues in HSS Journal, preclinical safety studies showed no adverse effects across several organ systems, yet no clinical safety data in humans was found. Reported side effects are generally mild:
- Mild nausea (more common with oral dosing)
- Injection site redness or irritation
- Dizziness (rare)
- Headache (rare)
Because BPC-157 promotes angiogenesis (new blood vessel formation), individuals with active cancer or a history of cancer should exercise caution and consult an oncologist before use. The same applies to anyone on blood thinners or with clotting disorders.
What does human research on BPC-157 show?
Human research on BPC-157 consists of small pilot and retrospective studies. A 2025 pilot study by Lee and Burgess gave intravenous BPC-157 to 2 healthy adults and reported no changes in heart, liver, kidney, thyroid or blood glucose markers. Two participants cannot establish safety for the doses or routes used in practice, and no randomized controlled trial has tested a BPC-157 dosage in people.
Competitive athletes should also know that the World Anti-Doping Agency (WADA) lists BPC-157 as a prohibited substance. For a wider look at peptide risks, read whether peptides are safe.
Where to Source BPC-157
Quality matters enormously with peptides. The market includes everything from compounded peptides prescribed by a clinician to research-grade products of questionable purity. Look for third-party certificates of analysis (COA) with HPLC purity testing, and avoid products sold as “research chemicals” without clear purity documentation.
Compounding access is limited and shifting. The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding, citing possible immunogenicity, peptide impurities and too little safety information to know whether it causes harm in humans. A licensed prescriber can explain what is currently available and how it is sourced.
How to Find a Clinic That Prescribes BPC-157
BPC-157 is usually offered by clinics that provide peptide therapy, along with related peptides such as TB-500, GHK-Cu and KPV. You can compare peptide therapy clinics in the Regenerated.com directory by state and city. Visits are generally cash pay, and insurance rarely covers off-label peptides.
Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means a clinic completed credential checks rather than paid more, and the directory is free for patients. Inclusion in the directory is not an endorsement. When you call a clinic, ask who prescribes, how the peptide is sourced, which dose and cycle they plan, and how they will follow up.
Frequently Asked Questions
Can I take BPC-157 on an empty stomach?
Yes. Oral BPC-157 is usually taken on an empty stomach, such as 30 minutes before a meal, because practitioners believe food can interfere with absorption, though this has not been tested in human studies. For injectable BPC-157, food intake does not matter, and the dose can be given at any time of day. Most people who split their dose inject once in the morning and once in the evening.
How quickly does BPC-157 start working?
Many users report noticeable improvement within 1 to 2 weeks of subcutaneous BPC-157, based on practitioner and user reports rather than clinical trials. Gut-related applications using oral dosing may take 1 to 3 weeks or longer. Severe or chronic injuries may require a full 4 to 6 week cycle before significant changes appear, and some people notice no change at all.
Is BPC-157 legal?
BPC-157 is not FDA approved for any medical use. The FDA lists it among bulk drug substances that may present significant safety risks in compounding, which has limited access through compounding pharmacies in the US. It is still sold online as a “research chemical” not intended for human use. Regulations vary by country, and the World Anti-Doping Agency prohibits it in sport.
Can I use BPC-157 after surgery?
Some practitioners recommend BPC-157 after surgery to support tissue healing, although no human trial has studied post-operative use. Timing varies, but starting a few days after surgery, once bleeding risk has subsided, is a common approach. Because BPC-157 affects blood vessel growth, always discuss it with your surgeon first, especially if you take blood thinners.
Do I need to refrigerate BPC-157?
Yes, once it is mixed. Lyophilized (powder) BPC-157 is stable at room temperature for extended periods, though refrigeration extends shelf life. Once reconstituted with bacteriostatic water, it must be refrigerated and is generally used within 3 to 4 weeks. Keep the vial away from light and heat, and do not freeze the mixed solution.
Can BPC-157 and TB-500 be mixed in the same syringe?
Yes. Many users draw both peptides into a single insulin syringe and inject them together at the same site. There is no known interaction that degrades either compound when combined, though no stability study has tested the mix. Draw each peptide separately using its own concentration, so the BPC-157 units and the TB-500 units are both measured correctly.
